Variability in response to short-acting β2-agonists (eg, albuterol) among patients with
asthma from diverse racial/ethnic groups may contribute to asthma disparities. We sought to …

Rationale: Albuterol, a bronchodilator medication, is the first-line therapy for asthma
worldwide. There are significant racial/ethnic differences in albuterol drug response …

Background The primary rescue medication to treat acute asthma exacerbation is the short-
acting β 2-adrenergic receptor agonist; however, there is variation in how well a patient …

Genome-wide association studies (GWAS) of response to asthma medications have
primarily focused on Caucasian populations, with findings that may not be generalizable to …

Short-acting β2-adrenergic receptor agonists (SABAs) are the most commonly prescribed
asthma medications worldwide. Response to SABAs is measured as bronchodilator drug …

Abstract Background and Objectives Genome Wide Association Studies (GWAS) have
identified genetic polymorphisms associated with bronchodilator response (BDR), but it is …

Bronchodilator (BD) drugs are commonly prescribed for treatment and management of
obstructive lung function present with diseases such as asthma. Administration of BD …

Rationale: β2-Agonists are the most common form of treatment of asthma, but there is
significant variability in response to these medications. A significant proportion of this …

Asthma is a complex respiratory disease considered as the most common chronic condition
in children. A large genetic contribution to asthma susceptibility is predicted by the clustering …

Asthma is a common chronic condition in children, where the response to treatment can be
heterogeneous within a population. Genetic variations may partly explain the inconsistent …